Together, these findings suggestthat the pharmacological targeting of NPC1L1 may offer a novel approach to managingcerebrovascular disease, with potential implications for cognitive health.Subsequent investigations into the role of NPC1L1 inhibition in mitigating the riskof cognitive impairment associated with SVD is warranted, aiming to contribute tothe reduction of the global burden of aging-related cognitive decline. The gene discussed is NPC1L1; the disease is snowflake vitreoretinal degeneration.